



**ADVANCING RESEARCH.
ENABLING ACCESS.
ENHANCING HEALTH.**

CONTENTS

INTRODUCTION

- WHO ARE WE?
- VISION & MISSION
- AT A GLANCE

OUR FOCUS

- ACTIVE PHARMACEUTICAL INGREDIENTS
- FINISHED DOSAGES
- MSN BRANDED GENERICS
- CDMS (CONTRACT DEVELOPMENT & MANUFACTURING SERVICES)

MANUFACTURING

- OVERVIEW
- CAPACITIES
- API FACILITIES ACCREDITATIONS
- FDF FACILITIES ACCREDITATIONS

RESEARCH & DEVELOPMENT

- OVERVIEW
- CREDENTIALS & COUNTRY WISE DMFs

GLOBAL FOOTPRINT

- OUR REACH & PRESENCE
- NORTH AMERICA
- EUROPE
- EMERGING MARKETS & TOP BRANDS
- INDIA & TOP BRANDS

OUR STRENGTHS

- QUALITY
- THERAPIES
- PARTNERSHIPS
- RESPONSIBILITY
- PEOPLE

AWARDS & ACCOLADES



WHO ARE WE?

- Headquartered in Hyderabad, India, we are one of the fastest growing, research-based and fully integrated pharmaceutical companies
- Founded in 2003 by Dr. MSN Reddy, (CMD,MSN Group)
- Engaged in developing, manufacturing and marketing of best-in-class APIs & Finished Dosages.
- Global distinction for delivering products that epitomize quality, safety and affordability.



OUR VISION & MISSION

VISION

To emerge as a globally renowned pharmaceutical company offering high-quality, affordable medicines to the world while remaining committed to social and environmental responsibilities.

MISSION

To leverage our research & development capabilities for bringing affordable generics, swiftly and consistently, thereby contributing to the alleviation of life-threatening diseases and improving patients' lives.

AT A GLANCE

20

years of presence



Estd. 2003

100

countries



450+

APIs



300+

Formulations



21

state-of-the-art
manufacturing
facilities



30+

First-to-launch
generics

World
No. 1
in active
US DMF Filings



\$1 Bn

Revenues



20,000+

employees worldwide



35%

CAGR since 2005



**End-to-end
Integration**

R&D < APIs
< Finished Dosages

OUR FOCUS



**Active Pharmaceutical
Ingredients**



Finished Dosages



MSN Branded Generics



CDMS
(Contract Development
& Manufacturing Services)

SYNTHESISING SUCCESS



- Best-in-class APIs across multiple therapeutic areas
- 450+ products and counting
- Prostaglandins • Peptides • High potency APIs.

Proven expertise in :

- Oligonucleotides
- Organic Syntheses
- Heterocyclic chemistry
- Carbohydrates
- Solid Support Systems
- Achiral Chemistry
- Metal Chemistry
- Azido Nitroso Impurities' Characterization
- Genotoxic Impurities' Characterization
- Complex Peptides
- Iron Complexes
- Polymer Chemistry

FORMULATIONS FOR A HEALTHIER WORLD



- 300+ products in portfolio
- Diverse dosage forms & strengths
- Nanotechnology
- Presence in Ophthalmics
- Biosimilars in pipeline

Solid Orals (Tablets & Capsules) - Capabilities

- Intermittent Release
- Extended Release
- Sustained Release
- Modified Release (Osmotic)
- Multi-layered Formulations
- Sublinguals
- Pellets
- Granules

Liquid Orals - Capabilities

- Oral Suspensions
- Oral Solutions
- Syrups
- Drops
- Emulsions
- Mixtures etc.

Parenterals (Liquids & Lyo) - Capabilities

- Ampoules
- Vials
- Depot Injections
- PFS/Pens
- Auto-injectors etc.

GLOBAL ACCESS TO AFFORDABLE GENERICS



-
- 300+ products
 - Presence across 35+ therapies
 - 80+ geographies
-
- Driving our prescription based endeavours
 - Affordable medicines to patients
 - Strong presence in India with **top 5 selling brands**
 - Growing presence in high value markets like North America, Europe & Australia
 - Increasing market share in emerging markets like **LATAM, Asia & Africa**
 - Trusted by over **40 million** patients worldwide

CATALYSING PARTNERS' GROWTH

Tailored Solutions. | Fast-tracked drug development | Boosting partners' go-to market strategies



One Stop Shop –
Vertical Integration
– Intermediates –
API – Formulation




Experienced R&D
teams to develop
Non-Infringing
Products




Manufacturing
Capacities: Small to
Large Scale (API &
FDF)



Dedicated
Capacities



Regulatory
Compliances



Online Project
Management
Systems- Transparent
& Real Time
communications



Quality & On-time
Deliverables



Strong associations
with innovators



Financial Stability



MANUFACTURING EXCELLENCE

- OVERVIEW
- CAPACITIES
- API FACILITIES ACCREDITATIONS
- FDF FACILITIES ACCREDITATIONS



MANUFACTURING OVERVIEW

15 API **6** FDF

state-of-the-art & fully-integrated facilities.

- Fully compliant with c GMP (Current Good Manufacturing Practices)
- Maximized process automation; impeccable quality
- Constant upgradation of processes, technologies & equipment
- Audited by most stringent regulatory bodies of the world

API CAPACITIES



- Expansive manufacturing infrastructure
- Capability to deliver from grams to tonnes

2400

Reactors

8000kL

Total Volume

1500+

MT / Annum

KILO LAB (R&D)

30

Reactors

5kl

Total Volume

FDF CAPACITIES (Per Annum)



Tablets

~ 12 Billion

Capsules

~ 2.0 Billion

Sachets

~ 100 Mn.

Parenterals

~ 40 Mn.

(Lyo & Liquids)

Oral Suspensions

~ 7.0 Mn.

Granules

~ 100 Tons

API - FACILITY WISE ACCREDITATIONS



- MSN Laboratories- Rudraram
- MSN Laboratories II – Kardanoor
 - MSN Organics-Bibinagar
- MSN Pharmachem- Pashamylaram
 - Maithri Laboratories- Kazipally
- MSN Life Sciences I- Mambapur
- MSN Life Sciences II - Chegunta
- MSN Life Sciences III – Bhiknoor



- MSN Laboratories- Rudraram
- MSN Pharmachem- Pashamylaram
- Maithri Laboratories- Kazipally



- MSN Laboratories- Rudraram
- MSN Organics- Bibinagar



- MSN Laboratories- Rudraram
- MSN Pharmachem- Pashamylaram



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

- MSN Laboratories- Rudraram



WHO - GENEVA

- MSN Pharmachem- Pashamylaram



- MSN Laboratories- Rudraram
- MSN Pharmachem- Pashamylaram



SLOVENIA

- MSN Organics- Bibinagar

API - FACILITY WISE ACCREDITATIONS



ANVISA - BRAZIL

- MSN Laboratories- Rudraram
- MSN Laboratories II – Kardanoor



Comisión Federal para la Protección
contra Riesgos Sanitarios

- MSN Laboratories- Rudraram
- MSN Laboratories II – Kardanoor
 - MSN Organics-Bibinagar
- MSN Pharmachem- Pashamylaram



Australian Government

Department of Health

- Maithri Laboratories- Kazipally
- MSN Life Sciences II - Chegunta



- MSN Laboratories- Rudraram
- MSN Organics-Bibinagar
- MSN Pharmachem- Pashamylaram



MOH - RUSSIA

- MSN Laboratories- Rudraram
- MSN Laboratories II – Kardanoor
- MSN Pharmachem- Pashamylaram
- MSN Life Sciences II - Chegunta















- MSN Laboratories- Rudraram
- MSN Pharmachem- Pashamylaram

FDF - FACILITY WISE ACCREDITATIONS

MSN Labs, Bollaram

 MHRA - UK	 SAUMP - UKRAINE	 MOH - ROMANIA	 ANVISA - BRAZIL	 INVIMA - COLOMBIA	 MOH - PERU	 FDA - TAIWAN
 KSFDA - SAUDI	 MOH - UAE	 MOH - QATAR	 MOH - JORDAN	 MOH - YEMEN	 PPB - KENYA	 MCAZ - ZIMBABWE
 TFDA - TANZANIA	 FMHA - ETHIOPIA	 NAFDAC - NIGERIA	 MOH - NAMIBIA	 PMRB - MALAWI	 NDA - UGANDA	 ISO 9001 :2008
 WHO - GENEVA	MSN Labs, Mekaguda		 US FDA	 SIDC - SLOVAKIA		

MSN Labs, Kothur

 US FDA	 MHRA - UK	 Hamburg BGV - GERMANY
 ANVISA - BRAZIL	 SIDC - CZCH REPUBLIC	 SIDC - SLOVAKIA
 PPB - KENYA	 DSIR - INDIA	 ISO 9001 :2008
 Pharmaceuticals Inc.	 US FDA	 DEA



RESEARCH & DEVELOPMENT

- OVERVIEW
- CREDENTIALS
- COUNTRY WISE DMFs

UNRAVELING NEW FRONTIERS OF EXCELLENCE



-
- Emphasis on speed and consistency
 - Helping us rapidly expand our product portfolio

-
- One of Asia's largest Integrated R&D centre; allows APIs and Finished Dosages' research under one roof
 - 2200+ top-notch experts dedicated to R&D
 - Pilot plant for scale-up studies
 - Proven capability in: • Niche generics • Complex and Difficult-to-make APIs & Formulations • NCEs • Novel Drug Delivery Systems (NDDS)

RESEARCH CREDENTIALS

50

State-of-the-art
Laboratories



900+

Natl. & Intl. patent
applications

150+

Granted



182

PCTs



1000+

Global DMFs



8000+

Dossiers

2400+

Approved



50+

First-to-Files



160+

ANDAs



Approved by:



COUNTRY WISE DMFs



US
455



EU
138



CEP
121



CANADA
96



CHINA
67




KOREA
82



TAIWAN
67



RUSSIA
46



JAPAN
13

TOTAL
1,085



GLOBAL FOOTPRINT

- OUR REACH & PRESENCE
- NORTH AMERICA
- EUROPE
- EMERGING MARKETS & TOP BRANDS
- INDIA & TOP BRANDS

OUR REACH & PRESENCE



- Well-entrenched network of global offices, subsidiaries and partners
- Enabling swifter access to affordable medicines
- Presence in 80+ countries and growing



NORTH AMERICA

Presence strengthened by Novadoz and MSN Pharmaceuticals Inc. | Established to accelerate our growth in key markets like US, Canada & EU



- State-of-the-art finished dosages facility based at Piscataway, New Jersey.
- Aimed at supporting Group's product portfolio, CDM Services & **Made-in-America endeavors**
- Capability to produce high quality solid orals, liquids & powders including pellets and granules
- DEA approved facility to handle up to schedule I -V drugs with huge capacities of Vault and Cage




- Sales and marketing subsidiary for MSN Group's finished dosages portfolio
- Currently marketing oral solids (tablets, capsules) & injectables
- including oncology and specialty products.

EUROPE





-
- Wholly-owned marketing subsidiary - Vivanta Generics
 - Strategically located warehouses in UK, Spain & Malta for seamless supply
 - Dedicated QP release professionals for UK & Europe ensuring top quality products
-
- Established in 2018
 - Headquartered in UK; Offices in Czech Republic & Malta
 - 5 EU authorities' approved facilities
 - 40+ Dossiers Filed & 50 more in pipeline (3yrs)
 - Over 700 MAs (Majority Customers)
 - Offerings : • B2B • B2C • CMO+

EMERGING MARKETS OVERVIEW



REGIONS	LATAM	AFRICA	MENA	ASIA	CEE	CIS
NO. OF COUNTRIES PRESENT	18	22	12	09	07	04

EMERGING MARKETS TOP BRANDS



INDIA



-
- 190+ differentiated & bioequivalent products
 - Ranked among top 10 trusted brands as per IQVIA data
-

- 1100+ field force covering 90,000 medical professionals and top healthcare institutions

Pioneering products in:

- CNS • Diabetology • Oncology • Urology
- Pulmonary Arterial Hypertension • Dilutional Hyponatremia • Pain Management • Antiulcerants
- Over Active Bladder etc.

INDIA TOP BRANDS

DAPAONE
Dapagliflozin 5 / 10 mg Tablets

DDR
Dexlansoprazole MR 30/60 mg capsules

Empaone
Empagliflozin 10 / 25 mg Tablets

Levilex
Levetiracetam Tablets USP
250/500/750/1000 mg
Oral Solution I.P. 100 ml
I.V. Infusion 5ml
IN charge

PAH-20
Sildenafil 20mg Tablets

Pulmonext
Ambrisentan 5/10 mg Tablets

Pulmonext Kit
Combi-pack of Ambrisentan 5 mg + Tadalafil 20 mg Tablets

Pulmofib
Pirfenidone 267 / 801 mg Tablets

RejuLox-C
Aflapin 50mg + Native Collagen Type II 20mg Capsules

Tapal
Tapentadol Scored Tablets
50 mg
100 mg

Tofadoz
Tofacitinib 5 mg Tablets

TOLVAT
Micronized Tolvaptan 15 / 30 mg Tablets



GLOBAL FOOTPRINT

- QUALITY
- THERAPIES
- PARTNERSHIPS
- RESPONSIBILITY
- PEOPLE
- AWARDS & ACCOLADES

UNCOMPROMISING QUALITY













-
- Recognized for one quality standard globally
 - Record of seven back-to-back successful USFDA audits
-

- 2000+ quality experts
- Integrated quality systems & processes
- LIMS enabled QA/QC labs
- High quality standards at every step, from procurement to final product

OUR THERAPEUTIC OFFERINGS

35+

Therapeutic
Categories &
Counting



FORGING STRONG PARTNERSHIPS



-
- Preferred partner for innovators, world's leading generics companies and global procurement bodies.
 - Enables our mission to bring new and life-saving medicines early to the market
-

What makes us a preferred partner?

- Robust manufacturing infrastructure
- Backward integration capabilities
- Proven expertise
- Trusted quality
- Respect for International Patent Rights

Partnered with MPP (Medicines Patent Pool) to launch MSD's Molnupiravir & in-license Pfizer's Paxlovid.

OUR PARTNERS IN PROGRESS



API TOP 10



FDF TOP 10



OTHER VALUABLE PARTNERS



ONCOLOGY THERAPY INITIATIVES

ASCO JCO
Digital library



Offers easy access to the latest & most credible, peer-reviewed resources in oncology that informs delivery of high-quality patient care



- Global updates in areas of interest of our existing portfolio

CANCER CONFERENCE SINCE 2021



CAMPAIGN



ASCO DIGITAL LIBRARY

5 High impact Journals


Journal of Clinical Oncology®
JCO® Oncology Practice
JCO® Global Oncology
JCO® Clinical Cancer Informatics
JCO® Precision Oncology

Trending News

ASCO Daily News®
The ASCO Post
ASCO Connection


Step 1:

- On the MSN Home Page, Go to **Library** tab



Step 2:


- Under **Library** tab, go to **ASCO JCO Digital Library** option



Login

Step 3:

- On the login page, enter **User Name & password** and click on login (User name & password will be provided by CANFI team)



CANFI TIMES



Canfi Times
Fight Against Cancer

INSIDE

- Global Updates
- Management of Treatment-Related Complications in OncoCare
- Tech Update
- Predicting patients at risk of chemotherapy-induced nausea and vomiting with a smartphone-based decision support tool
- In Spotlight
- Identification of fosaprepitant as a promising OCTPI inhibitor via structure-based virtual screening, molecular dynamics simulation, and biological assessment
- Conference Updates
- MASCC/ASCO Annual Meeting 2021
- FAQs
- Crossword
- Book Review

Global Updates

Management of Treatment-Related Complications in OncoCare

Epidemiology

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent and severe side effects of cancer treatment. Chemotherapeutic regimens can be categorized as having high, moderate, low, or minimal emetogenic risk. The CINV incidence and timing differ according to patient factors and chemotherapeutic agents. The incidence of CINV has been reported in 70-80% of patients and can have a significant impact on a patient's quality of life.¹

Nausea and vomiting can be grouped as acute, delayed, anticipatory, breakthrough, refractory, and chronic. Anticipatory nausea affects about 29% of patients receiving chemotherapy, while anticipatory vomiting affects 11% of patients. The prevalence of acute nausea and vomiting with moderate- or high-risk chemotherapy ranges from 30% to 90%.²

Risk factors

Most patients receiving chemotherapy are at risk of nausea and vomiting (N&V), but the onset, severity, triggers, and duration may differ. Tumor location, chemotherapy agents used, and radiation exposure all contribute to nausea and vomiting.³

Patient-related factors may include:³

Nausea and vomiting during past chemotherapy cycles

History of chronic alcohol use


Age younger than 50 years

Female gender

History of morning sickness or emesis during pregnancy

ISSUE 1: SUPPORTIVE CARE

- How supportive care is of primary importance for mainstay treatment and better Quality of Life



Canfi Times
Fight Against Cancer

INSIDE

- Global Updates
- Updates in the Field of MDS
- A new scoring system for MDS introduced - The IPSS-Molecular Scoring System
- Precision medicine - Novel agents being investigated
- Research & Development
- Lenalidomide may prolong overall survival in low-risk, transfusion-dependent MDS
- Relapse and disease-free survival in MDS patients undergoing allo-HCT: Older matched sibling vs. younger matched unrelated donors
- Tech Update
- Machine learning assisted real-time deformability cytometry for identification of patients with MDS
- In Spotlight
- Convention News
- FAQs
- Crossword
- Book Review
- Humor

Myelodysplastic Syndromes

Global Updates

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic cancers. MDS results in morphologic bone marrow dysplasias and cytopenias (anemia, neutropenia, or thrombocytopenia) with a risk of progression to acute myeloid leukemia (AML).^{1,2}

Epidemiology^{3,4}

- Increases with age; median age at diagnosis around 70 years
- Global incidence of MDS estimated as 0.06-0.26 per 100,000
- Prevalence estimated to range from 0.22-13.2 per 100,000

Risk factors⁴


- Advanced age
- Previous exposure to chemotherapy/radiation therapy
- Being male
- Environmental/occupational exposure to benzene, other chemicals
- Autoimmune disorders
- Genetic predisposition; bone marrow failure syndromes may increase risk

Estimated number of leukemia cases⁵

Region	New cases (Absolute number)	
	2020	2040 (Estimated)
Africa	32138	55902
Asia	230650	31614
Latin America and Caribbean	38256	55771

ISSUE 2: HEMATOLOGY

- What's new in Multiple Myeloma , Myelodysplastic syndrome & Acute Myeloid Leukaemia



Canfi Times
Fight Against Cancer

CURRENT UPDATES IN PROSTATE CANCER

INSIDE

- News Update: Prostate Cancer
- Global Overview of Prostate Cancer Incidence and Mortality in 89 Countries from 2000 to 2019
- Delving into the Recent Advances in Prostate Cancer Management
- Deciphering the Modern paradigms for detection and management of prostate cancer
- Tolerability of Olaparib and Management of Common Adverse Events in Patients with Metastatic Castration-Resistant Prostate Cancer
- Exploring the Science-and-technology-led Innovations in Prostate Cancer
- Enhanced Prostate Cancer Detection Accuracy and Positive Predictive Value of PSA with Circulating Chromosome Conformation Signatures
- A Narrative Review of Functionality and Efficacy of Micro-Ultrasound for Prostate Cancer Detection
- A Focus on Abiraterone
- Comparison of the efficacy of abiraterone acetate with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone for high-risk hormone-naïve metastatic prostate cancer
- Highlights of the ESMO Asia Congress 2022
- Frequently Asked Questions
- Humor

News Update: Prostate Cancer

Global Overview of Prostate Cancer Incidence and Mortality in 89 Countries from 2000 to 2019

In 2020, prostate cancer was responsible for an estimated 1,414,000 new cases and 375,304 deaths worldwide, making it the second most common cancer and the 5th leading cause of cancer-related deaths in men. It is worth mentioning that prostate cancer is the most diagnosed cancer in 112 countries and the primary cause of cancer death in 48 countries. The prevalence of prostate cancer is projected to increase due to the aging population and economic growth.

Figure 1: Incidence and mortality of prostate cancer by continent in 2020.

(A) Incidence rate, (B) Mortality rate

(A) Incidence rate (1/10⁵)

Continent	Incidence rate (1/10 ⁵)	Crude rate	ASR
Oceania	70.3	105	105
Northern America	73	131.2	131.2
Latin American and the Caribbean	52	64.7	64.7
Europe	61.4	104	104
Asia	15.6	15.6	15.6
Africa	13.4	13.4	13.4


(B) Mortality rate (1/10⁵)

Continent	Mortality rate (1/10 ⁵)	Crude rate	ASR
Oceania	11	22.3	22.3
Northern America	8.3	20.4	20.4
Latin American and the Caribbean	4.3	10.6	10.6
Europe	11	22.9	22.9
Asia	11	11	11
Africa	7	10.3	10.3


ISSUE 3: SOLID TUMOR

- What's new in management of Prostate Cancer, Breast Cancer & Colorectal cancer

FRIENDS IN JOURNEY CAMPAIGN



Digital Flyer



Teaser



CANFI GLOBAL CONCLAVE 2023



3rd Global Conclave 2023
3rd to 7th May 2023 | Hyderabad, India

Theme:
Integrating Global Perspectives
into Individualized Practices



PARTICIPATED COUNTRIES

- Kenya
- Ghana
- Uganda
- Namibia
- Sri Lanka
- Colombia
- Peru
- Chile
- Trinidad and Tobago





CANFI GLOBAL CONCLAVE 2023

3rd Global Conclave 2023

3rd to 7th May 2023 | Hyderabad, India



PARTICIPATED COUNTRIES

- Kenya
- Ghana
- Uganda
- Namibia
- Sri Lanka
- Colombia
- Peru
- Chile
- Trinidad and Tobago



CARDIOLOGY THERAPY INITIATIVES


CARDIOLOGY CONFERENCE SINCE 2018




Rhythm Mobile App



Echo Training



Echocardiography is currently the most widely used non-invasive imaging test for the evaluation of known or suspected heart disease.



Conventional techniques: M-mode, 2-dimensional / B-mode imaging, pulsed, continuous wave, and color Doppler imaging.

Global Conference Updates

**ESC Congress
2023 Amsterdam**



www.escard.org/ESC2023
#ESCCongress



**MARCH 4 - 6, 2023
NEW ORLEANS**



AMERICAN
COLLEGE of
CARDIOLOGY.



WORLD
HEART
FEDERATION



RHYTHM CARDIOLOGY UPDATES 2023

PARTICIPATED COUNTRIES

- Kenya
- Ghana
- Uganda
- Namibia
- Turkey
- Zambia
- Zimbabwe
- Saudi Arabia
- Tanzania
- Mauritius
- Mali
- Cambodia
- Congo
- Cameroon



MAKING A HEALTHY DIFFERENCE TO THE WORLD

- Deep-seated commitment to environmental and social sustainability
- Making a meaningful difference to both our planet and communities

CARING FOR ENVIRONMENT




Green Technologies & Eco-friendly Processes



Zero Discharge Facilities



Hazardous Waste Management Systems



50% Green Cover at all Manufacturing Sites



Solar Power for a Sustainable Future Etc.

CARING FOR COMMUNITIES

COMMUNITY HEALTH INITIATIVES



Compassionate
Medicine Programme



Preventive Health
Check-up Camps



Health & Patient
Awareness Initiatives



Free Health Kits &
Medicines' Distribution Etc.

COMMUNITY EMPOWERMENT INITIATIVES



Drinking Water



Education



Rural Infrastructure



Swachh Bharat & More...



OUR PEOPLE. OUR STRENGTH.



Motivated team of
14,000+ employees;
our greatest strength



“People First” approach



Environment where innovation
is encouraged, talents are
nurtured and growth is ensured



AWARDS & ACCOLADES

2008

- FAPCCI - R&D Excellence Award
- IES - Udyog Rattan Award



2009

- Scrip - Best Company in Emerging Markets
- PHARMEXCIL - Patent Award - Bulk Gold



2010

- PHARMEXCIL - Outstanding Export Award



2013

- CII Intellectual Property Award
- PHARMEXCIL - Patent Award - Bulk Gold



2012

- FAPCCI - Outstanding Export Award
- PHARMEXCIL - Outstanding Export Award
- ICCI -CNBC TV 18 – CRISIL - Emerging India Award



2011

- UBM India – Innovation in Cost.
- PHARMEXCIL - Patent Award - Bulk Gold
- Abbot Healthcare - Customer Centric Business Partner



2014

- PHARMEXCIL Patent Award - Bulk Gold
- EMC Transformer Award



2015

- PHARMEXCIL DMF Award



2014

- TV5 Business Leader Award
- PHARMEXCIL Patent Award - Gold



2021

- CII - Intellectual Property Award
- PHARMEXCIL Patent Award - Silver
- PHARMEXCIL -DMF Award



2017

- Informa Markets - Packaging Team of the Year
- Telangana State IP Award (TSIPA)
- CII - Intellectual Property Award



THANK YOU!

MSN Global HQ
H. No. 2-91/10 & 11 /MSN,
Whitefields, Kondapur,
Hyderabad, Telangana, India – 500084
Ph: +91 40 30438600

www.msnlabs.com

api@msnlabs.com

formulation@msnlabs.com

Follow us on:     